Medicine (Baltimore) 2016 Sep;95(37):e4638
Department of Colorectal Surgery, Wan Fang Hospital Department of Surgery, College of Medicine Division of General Surgery, Department of Surgery Cancer Center, Taipei Medical University Hospital Graduate Institute of Cancer Biology and Drug Discovery Department of General Surgery, Wan Fang Hospital, Taipei Medical University Department of Radiation Oncology, Taipei Medical University Hospital Institute of Toxicology, College of Medicine, National Taiwan University Department of Radiation Oncology, Wan Fang Hospital Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei Department of Biotechnology, Hungkuang University, Taichung, Taiwan.
To investigate the outcomes of the selective neoadjuvant concurrent chemoradiotherapy (CCRT) in lower 3rd rectal cancer patients in different groups (with or without neoadjuvant CCRT), especially in survival rate, local recurrence rate, and sphincter preservation rate.From January 1999 to December 2012, 69 consecutive patients who had histologically proven adenocarcinoma of lower 3rd rectum, defined preoperatively as lower tumor margin within 7 cm from the anal verge as measured by rigid sigmoidoscopy, received total mesorectum excision (TME). Our inclusion criteria of neoadjuvant CCRT are lower 3rd rectal cancer, stage II/III, and large (diameter >5 cm or >1/2 of circumference). Read More